Reporting owner · CIK 0001690298

Curran Terrie

Visual SEC Form 4 history across 2 companies, 11 transactions and 4 filings.

DIRArcutis Biotherapeutics, Inc.
Open-market mix
Latest filingAug 28, 2026, 09:40 PM
Filings4Form 4 records
Buying$00 purchases
Selling$1.1M4 sales
Net value−$1.1MBuys minus sells
Companies23 securities
Most recentAug 27, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-51Jan 25Feb 253Aug 26

Net value flow

Buys minus sells

Jan 25
−$125.9K
Feb 25
$0
Aug 26
−$984K

Transaction texture

Ownership and ticket size

Average P/S size$277.5K
Median P/S size$202.5K
Direct11
Indirect0
Aug 27, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern3Derivative Transactionfiling-context4Direct Ownershipfiling-context11Large Holdings Increaseholdings3Large Holdings Reductionholdings2Repeat Sellerpattern2

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Arcutis Biotherapeutics, Inc. on Aug 27, 2026 valued at $677,095.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Arcutis Biotherapeutics, Inc. on Aug 27, 2026 valued at $677,095.

Review SEC filing

Associated companies

Visual map of known reporting history

ARQTArcutis Biotherapeutics, Inc.9 transactions · latest Aug 28, 2026, 09:40 PMPHATPhathom Pharmaceuticals, Inc.2 transactions · latest Mar 03, 2025, 10:16 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
ARQTCurran Terrie
DIR
exercise27.0k$0M
Derivative Transaction Direct Ownership
—08/2808/27
ARQTCurran Terrie
DIR
exercise11.1k$0M
Derivative Transaction Direct Ownership
—08/2808/27
ARQTCurran Terrie
DIR
sale27.0k-$67.7MS
Cluster Selling Direct Ownership Large Holdings Reduction+1
—08/2808/27
ARQTCurran Terrie
DIR
exercise27.0k$23.3MM
Direct Ownership Large Holdings Increase
—08/2808/27
ARQTCurran Terrie
DIR
sale11.1k-$27.9MS
Cluster Selling Direct Ownership Large Holdings Reduction+1
—08/2808/27
ARQTCurran Terrie
DIR
exercise11.1k$8.37MM
Direct Ownership Large Holdings Increase
—08/2808/27
ARQTCurran Terrie
DIR
exercise1.07k$0M
Derivative Transaction Direct Ownership
+0.2%08/2408/20
ARQTCurran Terrie
DIR
sale1.07k-$2.79MS
Cluster Selling Direct Ownership
+0.2%08/2408/20
ARQTCurran Terrie
DIR
exercise1.07k$805kM
Direct Ownership
+0.2%08/2408/20
PHATCurran Terrie
PRESCE
grant342k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—03/03/202502/27/2025

Curran Terrie Insider Activity FAQ

SEC Form 4 context

Who is Curran Terrie?

Curran Terrie is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001690298.

Which companies has Curran Terrie reported transactions for?

Arcutis Biotherapeutics, Inc., Phathom Pharmaceuticals, Inc.

When was Curran Terrie's latest insider buy?

No open-market insider purchase is available for this period.

When was Curran Terrie's latest insider sale?

sale at Arcutis Biotherapeutics, Inc. on Aug 27, 2026 valued at $677,095.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.